Skip to main content
SpringerLink
Log in

Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Tumor necrosis factor (TNF)-α–based hyperthermic isolated limb perfusion (HILP) is one of the most active available approaches for locally advanced soft tissue sarcomas (STS) of the limbs. The aim of this study was to investigate the anticancer activity of a novel drug regimen including doxorubicin (DXR) and low-dose TNF-α.

Methods

HILP with low-dose TNF-α (1 mg) and DXR (8.5 mg/L of limb volume) was given to 21 patients with limb-threatening STS: 14 had primary and 7 had recurrent STS, most of which were high grade (grade 1, n = 3; grade 2, n = 6; grade 3, n = 12). Resection of the tumor remnant was performed 6 to 8 weeks after HILP. TNF-α concentrations in plasma and perfusate were measured throughout perfusion.

Results

A major tumor response was observed at histology and clinical evaluation in 90% and 62% of patients, respectively. After a median follow-up of 30 months, limb salvage and local disease control were achieved in 71% and 81% of cases, respectively. Fourteen patients had moderate regional toxicity, which was resolved in all cases. One patient had severe limb toxicity, which did not require amputation. Systemic side effects were minimal, and there were no postoperative deaths. The perfusate/plasma area under the curve ratio for TNF-α was 56.

Conclusions

HILP with low-dose TNF-α and DXR seems to be an active neoadjuvant drug regimen against limb-threatening STS. This therapeutic approach can achieve high limb-sparing surgery rates with acceptable local and negligible systemic toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. HJ Hoekstra HS Koops J Oldhoff (1994) ArticleTitleSoft tissue sarcoma of the extremity Eur J Surg Oncol 20 3–6 Occurrence Handle1:STN:280:ByuC2sfjvVM%3D Occurrence Handle8131865

    CAS  PubMed  Google Scholar 

  2. DA Potter J Glenn T Kinsella (1985) ArticleTitlePatterns of recurrence in patients with high-grade soft-tissue sarcomas J Clin Oncol 3 353–66

    Google Scholar 

  3. SJ Ham HJ Hoekstra H Schraffordt Koops WH Eisma J Oldhoff (1993) ArticleTitleThe interscapulothoracic amputation in the treatment of malignant diseases of the upper extremity with a review of the literature Eur J Surg Oncol 19 543–8 Occurrence Handle1:STN:280:ByuD1MvpsFI%3D Occurrence Handle8270041

    CAS  PubMed  Google Scholar 

  4. SJ Ham HJ Hoekstra WH Eisma H Schraffordt Koops J Oldhoff (1993) ArticleTitleThe Tikhoff-Linberg procedure in the treatment of sarcomas of the shoulder girdle J Surg Oncol 53 71–7 Occurrence Handle1:STN:280:ByyB2svos1A%3D Occurrence Handle8501909

    CAS  PubMed  Google Scholar 

  5. DJ Beech RE Pollock (1995) ArticleTitleSurgical management of primary soft tissue sarcoma Hematol Oncol Clin North Am 9 707–18 Occurrence Handle1:STN:280:BymD3MrgvV0%3D Occurrence Handle7490236

    CAS  PubMed  Google Scholar 

  6. A Stotter (1992) ArticleTitleComparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity Ann Surg 216 615–6 Occurrence Handle1:STN:280:ByyD2svitVU%3D Occurrence Handle1444656

    CAS  PubMed  Google Scholar 

  7. CR Rossi S Mocellin P Pilati M Foletto D Nitti M Lise (2003) ArticleTitleTNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: state of the art and future trends J Immunother 26 291–300 Occurrence Handle10.1097/00002371-200307000-00001 Occurrence Handle1:CAS:528:DC%2BD3sXmt1Onu7k%3D Occurrence Handle12843791

    Article  CAS  PubMed  Google Scholar 

  8. AM Eggermont JH Wilt Particlede TL ten Hagen (2003) ArticleTitleCurrent uses of isolated limb perfusion in the clinic and a model system for new strategies Lancet Oncol 4 429–37 Occurrence Handle10.1016/S1470-2045(03)01141-0 Occurrence Handle12850194

    Article  PubMed  Google Scholar 

  9. O Creech E Krementz R Ryan (1958) ArticleTitleChemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit Ann Surg 148 616–32 Occurrence Handle13583933

    PubMed  Google Scholar 

  10. ET Krementz RD Carter CM Sutherland I Hutton (1977) ArticleTitleChemotherapy of sarcomas of the limbs by regional perfusion Ann Surg 185 555–64 Occurrence Handle1:STN:280:CSiC1c%2Fls1A%3D Occurrence Handle266397

    CAS  PubMed  Google Scholar 

  11. HI Robins F d’Oleire M Kutz et al. (1995) ArticleTitleCytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia Cancer Lett 89 55–62 Occurrence Handle1:CAS:528:DyaK2MXjs1Crs74%3D Occurrence Handle7882302

    CAS  PubMed  Google Scholar 

  12. TS Herman (1983) ArticleTitleTemperature dependence of adriamycin, cis-diamminedichloroplatinum, bleomycin, and 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in vitro Cancer Res 43 517–20 Occurrence Handle1:CAS:528:DyaL3sXhtVSrtL8%3D Occurrence Handle6184147

    CAS  PubMed  Google Scholar 

  13. D Lienard P Ewalenko JJ Delmotte N Renard FJ Lejeune (1992) ArticleTitleHigh-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma J Clin Oncol 10 52–60 Occurrence Handle1:STN:280:By2D1M3gslQ%3D Occurrence Handle1727926

    CAS  PubMed  Google Scholar 

  14. AM Eggermont H Schraffordt Koops D Lienard et al. (1996) ArticleTitleIsolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial J Clin Oncol 14 2653–65 Occurrence Handle1:CAS:528:DyaK28XmsFCgtr0%3D Occurrence Handle8874324

    CAS  PubMed  Google Scholar 

  15. AM Eggermont H Schraffordt Koops JM Klausner et al. (1996) ArticleTitleIsolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience Ann Surg 224 756–64 Occurrence Handle10.1097/00000658-199612000-00011 Occurrence Handle1:STN:280:ByiC383pvVU%3D Occurrence Handle8968230

    Article  CAS  PubMed  Google Scholar 

  16. M Gutman M Inbar D Lev-Shlush et al. (1997) ArticleTitleHigh dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation Cancer 79 1129–37

    Google Scholar 

  17. M Vaglini F Belli M Ammatuna et al. (1994) ArticleTitleTreatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan Cancer 73 483–92 Occurrence Handle1:STN:280:ByuC38zisFA%3D Occurrence Handle8293417

    CAS  PubMed  Google Scholar 

  18. P Eggimann R Chiolero PG Chassot D Lienard J Gerain F Lejeune (1995) ArticleTitleSystemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs Chest 107 1074–82 Occurrence Handle1:STN:280:ByqB38%2Fgs1I%3D Occurrence Handle7705119

    CAS  PubMed  Google Scholar 

  19. F Villani M Galimberti G Mazzola et al. (1995) ArticleTitlePulmonary toxicity of alpha tumor necrosis factor in patients treated by isolation perfusion J Chemother 7 452–4 Occurrence Handle1:CAS:528:DyaK28XjsFOl Occurrence Handle8596131

    CAS  PubMed  Google Scholar 

  20. BC Vrouenraets BB Kroon AC Ogilvie et al. (1999) ArticleTitleAbsence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan Ann Surg Oncol 6 405–12 Occurrence Handle10.1007/s10434-999-0405-9 Occurrence Handle1:STN:280:DyaK1Mzgs1GgsA%3D%3D Occurrence Handle10379864

    Article  CAS  PubMed  Google Scholar 

  21. WC Barker MP Andrich HR Alexander DL Fraker (1995) ArticleTitleContinuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs Eur J Nucl Med 22 1242–8 Occurrence Handle10.1007/BF00801607 Occurrence Handle1:CAS:528:DyaK28XktVSgsA%3D%3D Occurrence Handle8575471

    Article  CAS  PubMed  Google Scholar 

  22. A Santoro T Tursz H Mouridsen et al. (1995) ArticleTitleDoxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J Clin Oncol 13 1537–45 Occurrence Handle1:STN:280:ByqA38ros1w%3D Occurrence Handle7602342

    CAS  PubMed  Google Scholar 

  23. CR Rossi M Foletto F Di Filippo et al. (1999) ArticleTitleSoft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion Cancer 86 1742–9 Occurrence Handle10.1002/(SICI)1097-0142(19991101)86:9<1742::AID-CNCR16>3.0.CO;2-G Occurrence Handle1:STN:280:DC%2BD3c%2Fhs1ejsA%3D%3D Occurrence Handle10547547

    Article  CAS  PubMed  Google Scholar 

  24. F Di Filippo CR Rossi M Vaglini et al. (1999) ArticleTitleHyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study J Immunother 22 407–14 Occurrence Handle1:CAS:528:DyaK1MXntlakt7k%3D Occurrence Handle10546156

    CAS  PubMed  Google Scholar 

  25. CR Rossi A Vecchiato M Foletto et al. (1994) ArticleTitlePhase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas Cancer 73 2140–6 Occurrence Handle1:STN:280:ByuB3cjpslA%3D Occurrence Handle8156518

    CAS  PubMed  Google Scholar 

  26. D Casara D Rubello P Pilati et al. (2004) ArticleTitleOptimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99m Tc-HSA Nucl Med Commun 25 61–6 Occurrence Handle10.1097/00006231-200401000-00009 Occurrence Handle1:STN:280:DC%2BD2c7mslertQ%3D%3D Occurrence Handle15061266

    Article  CAS  PubMed  Google Scholar 

  27. J Wieberdink C Benckhuysen RP Braat EA van Slooten GA Olthuis (1982) ArticleTitleDosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions Eur J Cancer Clin Oncol 18 905–10 Occurrence Handle10.1016/0277-5379(82)90235-8 Occurrence Handle1:STN:280:BiyC3s7nslc%3D Occurrence Handle6891640

    Article  CAS  PubMed  Google Scholar 

  28. TR Fleming (1982) ArticleTitleOne-sample multiple testing procedure for phase II clinical trials Biometrics 38 143–51 Occurrence Handle1:STN:280:Bi2B3cnptlY%3D Occurrence Handle7082756

    CAS  PubMed  Google Scholar 

  29. AM Eggermont TL ten Hagen (2001) ArticleTitleIsolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives Curr Oncol Rep 3 359–67 Occurrence Handle1:STN:280:DC%2BD3MzhvFOktA%3D%3D Occurrence Handle11389822

    CAS  PubMed  Google Scholar 

  30. FJ Lejeune N Pujol D Lienard et al. (2000) ArticleTitleLimb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities Eur J Surg Oncol 26 669–78 Occurrence Handle10.1053/ejso.2000.0979 Occurrence Handle1:STN:280:DC%2BD3M%2Fms1Squw%3D%3D Occurrence Handle11078614

    Article  CAS  PubMed  Google Scholar 

  31. D Lev-Chelouche S Abu-Abeid Y Kollander et al. (1999) ArticleTitleMultifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan J Surg Oncol 70 185–9 Occurrence Handle10.1002/(SICI)1096-9098(199903)70:3<185::AID-JSO8>3.0.CO;2-# Occurrence Handle1:STN:280:DyaK1M3gtVCksQ%3D%3D Occurrence Handle10102350

    Article  CAS  PubMed  Google Scholar 

  32. BE Plaat WM Molenaar MF Mastik et al. (1999) ArticleTitleHyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis Clin Cancer Res 5 1650–7 Occurrence Handle1:CAS:528:DyaK1MXltVCqsbs%3D Occurrence Handle10430064

    CAS  PubMed  Google Scholar 

  33. H Schraffordt Koops AM Eggermont D Lienard et al. (1998) ArticleTitleHyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas Semin Surg Oncol 14 210–4 Occurrence Handle10.1002/(SICI)1098-2388(199804/05)14:3<210::AID-SSU4>3.0.CO;2-B Occurrence Handle1:STN:280:DyaK1c3gvVersQ%3D%3D Occurrence Handle9548603

    Article  CAS  PubMed  Google Scholar 

  34. S Hill WJ Fawcett J Sheldon N Soni T Williams JM Thomas (1993) ArticleTitleLow-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion Br J Surg 80 995–7 Occurrence Handle1:STN:280:ByuD3crmt1Y%3D Occurrence Handle8402100

    CAS  PubMed  Google Scholar 

  35. RB Alexander WG Nelson DS Coffey (1987) ArticleTitleSynergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II Cancer Res 47 2403–6 Occurrence Handle1:CAS:528:DyaL2sXktlaktro%3D Occurrence Handle2436763

    CAS  PubMed  Google Scholar 

  36. N Watanabe Y Niitsu N Yamauchi et al. (1988) ArticleTitleSynergistic cytotoxicity of recombinant human TNF and various anti-cancer drugs Immunopharmacol Immunotoxicol 10 117–27 Occurrence Handle1:CAS:528:DyaL1cXhsl2ks7k%3D Occurrence Handle2452179

    CAS  PubMed  Google Scholar 

  37. N Watanabe Y Niitsu H Umeno et al. (1988) ArticleTitleSynergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia Cancer Res 48 650–3 Occurrence Handle1:STN:280:BieD1c%2FgvFA%3D Occurrence Handle3335027

    CAS  PubMed  Google Scholar 

  38. MF Dubois C Ferrieux P Lebon (1989) ArticleTitleSynergistic cytotoxic effects of recombinant human tumor necrosis factor, interferons, and heat-stress Cancer Res 49 5618–22 Occurrence Handle1:CAS:528:DyaL1MXmtlSnt7k%3D Occurrence Handle2477147

    CAS  PubMed  Google Scholar 

  39. AH Veen Particlevan der JH de Wilt AM Eggermont ST van Tiel AL Seynhaeve TL ten Hagen (2000) ArticleTitleTNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects Br J Cancer 82 973–80 Occurrence Handle10.1054/bjoc.1999.1027 Occurrence Handle10732774

    Article  PubMed  Google Scholar 

  40. M Santinami M Deraco A Azzarelli et al. (1996) ArticleTitleTreatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan Tumori 82 579–84 Occurrence Handle1:CAS:528:DyaK2sXisFWqs7s%3D Occurrence Handle9061068

    CAS  PubMed  Google Scholar 

  41. AM Eggermont H Schraffordt Koops JM Klausner et al. (1997) ArticleTitleIsolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas Semin Oncol 24 547–55 Occurrence Handle1:STN:280:DyaK1c%2FgtlSjtA%3D%3D Occurrence Handle9344321

    CAS  PubMed  Google Scholar 

  42. MG Rosenblum NJ Donato JU Gutterman (1988) ArticleTitleCharacterization of human recombinant tumor necrosis factor-alpha antiproliferative effects on human cells in culture Lymphokine Res 7 107–17 Occurrence Handle1:CAS:528:DyaL1cXkslWktLY%3D Occurrence Handle2457138

    CAS  PubMed  Google Scholar 

  43. JF Buell E Reed KB Lee et al. (1997) ArticleTitleSynergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells Ann Surg Oncol 4 141–8 Occurrence Handle1:STN:280:ByiB3sbhs1c%3D Occurrence Handle9084851

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy

    Carlo Riccardo Rossi MD, Simone Mocellin MD, Pierluigi Pilati MD, Mirto Foletto MD, Luca Campana MD & Mario Lise MD

  2. Department of Pharmacology and Anesthesiology, University of Padova, Largo Meneghetti, 2, 35131, Padova, Italy

    Luigi Quintieri PhD

  3. Clinical Epidemiology Unit, Regional Oncology Centre, Via Gattamelata, 6, 4, 35128, Padova, Italy

    Gian Luca De Salvo MD

Authors
  1. Carlo Riccardo Rossi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simone Mocellin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierluigi Pilati MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mirto Foletto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luca Campana MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luigi Quintieri PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gian Luca De Salvo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mario Lise MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Riccardo Rossi MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rossi, C.R., Mocellin, S., Pilati, P. et al. Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas. Ann Surg Oncol 12, 398–405 (2005). https://doi.org/10.1245/ASO.2005.12.038

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2005.12.038

Keywords

Search

Navigation